Evidence map›Paper›PMID 32978312›Full record

ArticlemBio2020

Antiviral Drug Discovery To Address the COVID-19 Pandemic.

Douglas D Richman

Abstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.European journal of medicinal chemistry reports · 2021
    Review
  3. The New GenerationMicroorganisms · 2021
    Article
  4. Existing Drugs Considered as Promising in COVID-19 Therapy.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Douglas D RichmanUniversity of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus), Director, The HIV Institute, Co-Director, San Diego Center for AIDS Research, Florence Seeley Riford Chair in AIDS Research (Emeritus), La Jolla, California, USA drichman@ucsd.edu.ORCID 0000-0003-0962-9254

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M

Indexed as

Antiviral AgentsPandemicsPneumonia, ViralSevere Acute Respiratory SyndromeBetacoronavirusCoronavirus InfectionsCOVID-19Cysteine EndopeptidasesDrug DiscoveryHumansIndolesSARS-CoV-2Viral Nonstructural ProteinsAntiviral AgentsCysteine EndopeptidasesIndolesViral Nonstructural Proteinsantiviral agentscoronavirusCOVID-19drug resistancehepatitis C virushuman immunodeficiency virusprotease inhibitorsSARS-CoV-2

Identifiers

PMID32978312
PMCPMC7520600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.